Donitriptan (INNTooltip International Nonproprietary Name; developmental code name F-11356) is a triptan drug which was investigated as an antimigraine agent but was never marketed. It acts as a selective serotonin 5-HT_1B and 5-HT_1D receptor agonist. The drug reached phase 2 clinical trials prior to the discontinuation of its development.

Donitriptan acts as a high-affinity, high-efficacy near-full agonist of the serotonin 5-HT_1B (K_i = 0.079–0.40 nM; E_maxTooltip maximal efficacy = 94%) and 5-HT_1D receptors (K_i = 0.063–0.50 nM; E_max = 97%), and is among the most potent of the triptan series of drugs. It is also notable and unique among most of the triptans in being a potent serotonin 5-HT_2A receptor agonist (EC₅₀Tooltip half-maximal effective concentration = 7.9 nM), albeit with about one or two orders of magnitude lower activational potency than at the serotonin 5-HT_1B and 5-HT_1D receptors.

Donitriptan is a tryptamine derivative, a 5-substituted derivative of tryptamine and 5-methoxytryptamine, and an analogue of the psychedelic drugs dimethyltryptamine (DMT) and 5-MeO-DMT.

The predicted log P of donitriptan is 1.32 to 2.2.

Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.